Effects of CYP2C19, MDR1, and interleukin 1-B gene variants on the eradication rate of Helicobacter pylori infection by triple therapy with pantoprazole, amoxicillin, and metronidazole

被引:30
|
作者
Gawronska-Szklarz, Barbara [1 ]
Siuda, Andrzej [2 ]
Kurzawski, Mateusz [1 ]
Bielicki, Dariusz [3 ]
Marlicz, Wojciech [3 ]
Drozdzik, Marek [1 ]
机构
[1] Pomeranian Med Univ, Dept Pharmacol, PL-70111 Szczecin, Poland
[2] Reg Hosp, Clin Dept Internal Dis, PL-66530 Drezdenko, Poland
[3] Pomeranian Med Univ, Dept Gastroenterol, PL-70111 Szczecin, Poland
关键词
CYP2C19; MDR1; Interleukin-1; beta; Genetic polymorphism; Peptic ulcer; H; pylori; Pharmacogenetics; PEPTIC-ULCER PATIENTS; C3435T POLYMORPHISM; CURE RATES; SUSCEPTIBILITY; LANSOPRAZOLE; MEPHENYTOIN; METABOLISM; OMEPRAZOLE; CLARITHROMYCIN; RESISTANCE;
D O I
10.1007/s00228-010-0818-1
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Eradication of H. pylori is an important treatment strategy in peptic ulcer patients. Current regimens of eradication consist of proton pump inhibitor (PPI) and two antibiotics. Effects of PPI may depend on their metabolism, and other factors important for the pathophysiology of peptic ulcer disease. Aim of the present study was to evaluate an association of CYP2C19, MDR1, and IL-1B polymorphisms with the eradication rate of H. pylori in Polish Caucasian patients treated with a triple therapy of pantoprazole, amoxicillin, and metronidazole. A total of 139 peptic ulcer patients, positive for H. pylori infection, were treated with triple therapy (pantoprazole + amoxicillin + metronidazole). Subsequently, the patients were divided into two groups (group 1, success, and group 2, failure of eradication after therapy) and genotyped by the PCR-RFLP method for the presence of CYP2C19 variant alleles (*2, *3, and *17), and MDR1 3435C > T and IL-1B +3954C > T polymorphisms. Pantoprazole serum concentrations were measured using the HPLC method. No significant differences in frequency or distribution of CYP2C19 genotypes were found between the two groups of patients (i.e., with successful H. pylori eradication and treatment failure). However, any carrier of defective CYP2C19*2/*2 genotype was found among patients with treatment failure. Similarly, MDR1 and IL-1B genotypes were found to be significantly associated with the success or failure of H. pylori eradication. Univariate and multivariate analysis of the genotypes did not reveal any significant association between the genotypes and H. pylori eradication. Pantoprazole concentrations differed significantly, and were the highest in patients with defective allele CYP2C19*2 carriers and lowest in hyperactive genotype homozygotes CYP2C19*17/*17. The results suggest that the CYP2C19 genotype contrary to MDR1 and IL-1B genotypes may have an impact on the efficacy of H. pylori eradication in peptic ulcer patients treated with pantoprazole in Polish Caucasian peptic ulcer patients administered pantoprazole, amoxicillin, and metronidazole.
引用
收藏
页码:681 / 687
页数:7
相关论文
共 50 条
  • [31] THE EFFECTS OF GENETIC POLYMORPHISMS OF THE MDR1 AND CYP2C19, 3A4, 3A5 IN PANTOPRAZOLE METABOLISM AND TREATMENT RESPONSE OF GASTRITIS
    Karaca, R.
    Kalkisim, S.
    Yuksel, I.
    Altinbas, A.
    Kilincalp, S.
    Yasar, U.
    Bozkurt, A.
    Babaoglu, M.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2014, 115 : 171 - 171
  • [32] Association of MDR1, CYP2D6, and CYP2C19 gene polymorphisms with prophylactic migraine treatment response
    Atasayar, Gulfer
    Eryilmaz, Isil Ezgi
    Karli, Necdet
    Egeli, Unal
    Zarifoglu, Mehmet
    Cecener, Gulsah
    Taskapilioglu, Ozlern
    Tunca, Berrin
    Yildirim, Oznur
    Ak, Secil
    Tezcan, Gulcin
    Can, Fatma Ezgi
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2016, 366 : 149 - 154
  • [33] Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin
    Kawabata, H
    Habu, Y
    Tomioka, H
    Kutsumi, H
    Kobayashi, M
    Oyasu, K
    Hayakumo, T
    Mizuno, S
    Kiyota, K
    Nakajima, M
    Kimoto, K
    Inokuchi, H
    Kawai, K
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 17 (02) : 259 - 264
  • [34] Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pylori infection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole), amoxycillin and clarithromycin in Japan
    Dojo, M
    Azuma, T
    Saito, T
    Ohtani, M
    Muramatsu, A
    Kuriyama, M
    DIGESTIVE AND LIVER DISEASE, 2001, 33 (08) : 671 - 675
  • [35] Influence of CYP2C19 polymorphism and helicobacter pylori genotype determined from gastric tissue samples on response to triple therapy for H pylori infection
    Furuta, T
    Sagehashi, Y
    Shirao, N
    Sugimoto, M
    Nakamura, A
    Kodaira, M
    Kenmotsu, K
    Nagano, M
    Egashira, T
    Ueda, K
    Yoneyama, M
    Ohashi, K
    Ishizaki, T
    Hishida, A
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2005, 3 (06) : 564 - 573
  • [36] Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype
    Inaba, T
    Mizuno, M
    Kawai, K
    Yokota, K
    Oguma, K
    Miyoshi, M
    Take, S
    Okada, H
    Tsuji, T
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2002, 17 (07) : 748 - 753
  • [37] Effect of Genotypic Differences in CYP2C19 and on Cure Rates for Helicobacter pylori Infection by Triple Therapy With Different Proton Pump Inhibitors
    Demir, Kadir
    Ormeci, Asli
    Emrence, Zeliha
    Gokturk, Suut
    Baran, Bulent
    Soyer, Ozlem Mutluay
    Akyuz, Filiz
    Karaca, Cetin
    Besisik, Fatih
    Kaymakoglu, Sabahattin
    Ustek, Duran
    GASTROENTEROLOGY, 2013, 144 (05) : S333 - S333
  • [38] Famotidine increases the cure rates of Helicobacter pylori infection by a triple therapy in patients with the homozygous extensive metabolizer genotype of CYP2C19
    Okudaira, K
    Furuta, T
    Shirai, N
    Miura, S
    GASTROENTEROLOGY, 2004, 126 (04) : A188 - A188
  • [39] Reliable Efficacy of 14-Day High Dose PPI Triple Therapy for Helicobacter pylori Eradication Independent Effect of CYP2C19 Genotype and High Prevalence of Metronidazole Resistance in Thailand
    Vilaichone, Ratha-korn
    Prasertpetmanee, Sanchai
    Mahachai, Varocha
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2012, 107 : S46 - S46
  • [40] RELIABLE EFFICACY OF 14-DAY HIGH DOSE PPI TRIPLE THERAPY FOR HELICOBACTER PYLORI ERADICATION INDEPENDENT EFFECT OF CYP2C19 GENOTYPE AND HIGH PREVALENCE OF METRONIDAZOLE RESISTANCE IN THAILAND
    Prasertpetmanee, S.
    Mahachai, V.
    Vilaichone, R.
    HELICOBACTER, 2012, 17 : 99 - 99